Debu Tripathy, editor-in-chief of CURE magazine, reports from the San Antonio Breast Breast Cancer Symposium where a study involving the PI3 kinase inhibitor pictilisib showed interesting results.
Debu Tripathy, editor-in-chief of CURE magazine, reports from the San Antonio Breast Breast Cancer Symposium where a study involving a PI3 kinase inhibitor showed interesting results.
While the clinical trial involving the investigational agent pictilisib with an aromatase inhibitor had only modest results, interest in this type of targeted therapy remains, particularly in different stages of the disease and in combination with other drugs.
You can read more on the study at "Early Phase Study Finds PI3K Inhibitor Pictilisib Helps a Subset of Advanced Breast Cancer Patients."
Mother with Stage 4 Breast Cancer and Her Family 'Focus on the Living'
July 27th 2023Christina McAmis’ cancer journey began when she found a lump while breastfeeding. The attorney and mother of three tells the “Cancer Horizons” podcast what the last nine years have been like for her and her family.
Listen